SCHEMBL23945383

SCHEMBL23945383

CCCCCCCCCCCCCCCCCNC(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 9/20 0.50
TSHR P16473 2/20 0.48
ALDH1A1 P00352 2/20 0.48
THRB P10828 1/20 0.44
ADH1B P00325 1/20 0.44
ADH1C P00326 1/20 0.44
ADH1A P07327 1/20 0.44
ADH4 P08319 1/20 0.44
ADH7 P40394 1/20 0.44
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
FAAH O00519 1/20 0.41
MAPK1 P28482 1/20 0.41
HRH4 Q9H3N8 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40
PPARA Q07869 2/20 0.39
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
XBP1 P17861 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3365367 1.00 EPHX1 (0.50) EPHX1TSHRALDH1A1THRBADH1B
SCHEMBL183108 1.00 EPHX1 (0.50) EPHX1TSHRALDH1A1THRBADH1B
SCHEMBL8417287 1.00 EPHX1 (0.50) EPHX1TSHRALDH1A1THRBADH1B
SCHEMBL6899503 1.00 EPHX1 (0.50) EPHX1TSHRALDH1A1THRBADH1B
SCHEMBL6899576 1.00 EPHX1 (0.50) EPHX1TSHRALDH1A1THRBADH1B
SCHEMBL23696489 1.00 EPHX1 (0.50) EPHX1TSHRALDH1A1THRBADH1B
SCHEMBL19038581 1.00 EPHX1 (0.50) EPHX1TSHRALDH1A1THRBADH1B
SCHEMBL7770496 1.00 EPHX1 (0.50) EPHX1TSHRALDH1A1THRBADH1B
SCHEMBL1026323 1.00 EPHX1 (0.50) EPHX1TSHRALDH1A1THRBADH1B
SCHEMBL6175347 1.00 EPHX1 (0.50) EPHX1TSHRALDH1A1THRBADH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352350-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-06-07 US disclosed
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352350-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 EPHX1 1684/4885TSHR 3319/4885ALDH1A1 2776/4885
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 EPHX1 1684/4885TSHR 3319/4885ALDH1A1 2776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.